Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab

被引:39
作者
Golay, J
Gramigna, R
Facchinetti, V
Capello, D
Gaidano, G
Introna, M
机构
[1] Ist Ric Farmacol Mario Negri, Lab Mol Immunohaematol, Dept Immunol & Cell Biol, I-20157 Milan, Italy
[2] Amedeo Avogadro Univ Eastern Piedmont, Dept Med Sci, Div Internal Med, Haematol Unit, Novara, Italy
关键词
rituximab; AIDS; lymphoma; immunotherapy; alemtuzumab;
D O I
10.1046/j.1365-2141.2002.03935.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rituximab (Mabthera) and alemtuzumab (Campath, Mabcampath) are non-conjugated IgG1 therapeutic monoclonal antibodies directed against the CD20 and CD52 surface antigens respectively. They are presently used in the therapy of indolent B-cell non-Hodgkin's lymphoma (B-NHL) and of B-cell chronic lymphocytic leukaemia, and are thought to act mainly through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Here we have analysed the capacity of these two monoclonal antibodies to lyse cell lines of acquired immunodeficiency syndrome (AIDS)-related B-NHL through either complement activation or antibody-dependent cytotoxicity. Rituximab strongly activated both CDC and ADCC against CD20-positive AIDS-NHL cells lines, inducing up to 60-98% and 20% specific lysis respectively. In contrast, alemtuzumab was a poor activator of CDC, even in the AIDS-NHL cell lines expressing high amounts of CD52, leading to a lysis of only 1-30%, whereas it was at least as strong as rituximab in inducing ADCC of the same lines (up to 30% specific lysis). Altogether, these data offer a first in vitro rationale supporting the therapeutic use of rituximab for CD20-positive AIDS-NHL.
引用
收藏
页码:923 / 929
页数:7
相关论文
共 42 条
  • [1] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
    Anderson, DR
    GrilloLopez, A
    Varns, C
    Chambers, KS
    Hanna, N
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 705 - 708
  • [2] IMPORTANCE OF ANTIGEN-SPECIFICITY FOR COMPLEMENT-MEDIATED LYSIS BY MONOCLONAL-ANTIBODIES
    BINDON, CI
    HALE, G
    WALDMANN, H
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (10) : 1507 - 1514
  • [3] HUMAN-ANTIBODY EFFECTOR FUNCTION
    BURTON, DR
    WOOF, JM
    [J]. ADVANCES IN IMMUNOLOGY, 1992, 51 : 1 - +
  • [4] Carbone A, 1997, AM J PATHOL, V150, P155
  • [5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [6] Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy
    Corbellino, M
    Bestetti, G
    Scalamogna, C
    Calattini, S
    Galazzi, M
    Meroni, L
    Manganaro, D
    Fasan, M
    Moroni, M
    Galli, M
    Parravicini, C
    [J]. BLOOD, 2001, 98 (12) : 3473 - 3475
  • [7] Czuczman MS, 2000, BLOOD, V96, p729A
  • [8] Czuczman MS, 1999, SEMIN ONCOL, V26, P88
  • [9] Epidemiology of AIDS-related tumours in developed and developing countries
    Dal Maso, L
    Serraino, D
    Franceschi, S
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (10) : 1188 - 1201
  • [10] Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the, cytotoxic activity of either drug alone
    Di Gaetano, N
    Xiao, Y
    Erba, E
    Bassan, R
    Rambaldi, A
    Golay, J
    Introna, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (04) : 800 - 809